Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis

Pedro M. Machado, Siba P Raychaudhuri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In addition to the critical need of measuring tools for drug development of spondyloarthritis (SpA), these tools are also valuable for patient management. An early diagnosis, determination of early therapeutic response, and monitoring therapeutic response have now become increasingly important because effective therapies are available, and therapies such as anti-tumor necrosis factor (TNF) drugs are even more effective if used in early disease stages. In this review, we focus on disease activity measurements and monitoring in axial SpA and psoriatic arthritis (PsA). Both axial SpA and PsA have heterogeneous clinical manifestations. Therefore, in addition to the measurement of each clinical domain, composite measures inclusive of all clinical domains can be very helpful and are more likely to give complete and reliable information about the disease activity. A major focus of this review is to describe the recently developed composite measures for axial SpA and PsA.

Original languageEnglish (US)
Pages (from-to)711-728
Number of pages18
JournalBest Practice and Research: Clinical Rheumatology
Volume28
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Psoriatic Arthritis
Therapeutics
Pharmaceutical Preparations
Early Diagnosis
Tumor Necrosis Factor-alpha

Keywords

  • Disease activity
  • Monitoring
  • Outcome measures
  • Psoriatic arthritis
  • Spondyloarthritis
  • Validity

ASJC Scopus subject areas

  • Rheumatology

Cite this

Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. / Machado, Pedro M.; Raychaudhuri, Siba P.

In: Best Practice and Research: Clinical Rheumatology, Vol. 28, No. 5, 2014, p. 711-728.

Research output: Contribution to journalArticle

@article{647c4ea9338c4d16948d0b29cf2b0b92,
title = "Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis",
abstract = "In addition to the critical need of measuring tools for drug development of spondyloarthritis (SpA), these tools are also valuable for patient management. An early diagnosis, determination of early therapeutic response, and monitoring therapeutic response have now become increasingly important because effective therapies are available, and therapies such as anti-tumor necrosis factor (TNF) drugs are even more effective if used in early disease stages. In this review, we focus on disease activity measurements and monitoring in axial SpA and psoriatic arthritis (PsA). Both axial SpA and PsA have heterogeneous clinical manifestations. Therefore, in addition to the measurement of each clinical domain, composite measures inclusive of all clinical domains can be very helpful and are more likely to give complete and reliable information about the disease activity. A major focus of this review is to describe the recently developed composite measures for axial SpA and PsA.",
keywords = "Disease activity, Monitoring, Outcome measures, Psoriatic arthritis, Spondyloarthritis, Validity",
author = "Machado, {Pedro M.} and Raychaudhuri, {Siba P}",
year = "2014",
doi = "10.1016/j.berh.2014.10.004",
language = "English (US)",
volume = "28",
pages = "711--728",
journal = "Best Practice and Research in Clinical Rheumatology",
issn = "1521-6942",
publisher = "Bailliere Tindall Ltd",
number = "5",

}

TY - JOUR

T1 - Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis

AU - Machado, Pedro M.

AU - Raychaudhuri, Siba P

PY - 2014

Y1 - 2014

N2 - In addition to the critical need of measuring tools for drug development of spondyloarthritis (SpA), these tools are also valuable for patient management. An early diagnosis, determination of early therapeutic response, and monitoring therapeutic response have now become increasingly important because effective therapies are available, and therapies such as anti-tumor necrosis factor (TNF) drugs are even more effective if used in early disease stages. In this review, we focus on disease activity measurements and monitoring in axial SpA and psoriatic arthritis (PsA). Both axial SpA and PsA have heterogeneous clinical manifestations. Therefore, in addition to the measurement of each clinical domain, composite measures inclusive of all clinical domains can be very helpful and are more likely to give complete and reliable information about the disease activity. A major focus of this review is to describe the recently developed composite measures for axial SpA and PsA.

AB - In addition to the critical need of measuring tools for drug development of spondyloarthritis (SpA), these tools are also valuable for patient management. An early diagnosis, determination of early therapeutic response, and monitoring therapeutic response have now become increasingly important because effective therapies are available, and therapies such as anti-tumor necrosis factor (TNF) drugs are even more effective if used in early disease stages. In this review, we focus on disease activity measurements and monitoring in axial SpA and psoriatic arthritis (PsA). Both axial SpA and PsA have heterogeneous clinical manifestations. Therefore, in addition to the measurement of each clinical domain, composite measures inclusive of all clinical domains can be very helpful and are more likely to give complete and reliable information about the disease activity. A major focus of this review is to describe the recently developed composite measures for axial SpA and PsA.

KW - Disease activity

KW - Monitoring

KW - Outcome measures

KW - Psoriatic arthritis

KW - Spondyloarthritis

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=84927943402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927943402&partnerID=8YFLogxK

U2 - 10.1016/j.berh.2014.10.004

DO - 10.1016/j.berh.2014.10.004

M3 - Article

C2 - 25488780

AN - SCOPUS:84927943402

VL - 28

SP - 711

EP - 728

JO - Best Practice and Research in Clinical Rheumatology

JF - Best Practice and Research in Clinical Rheumatology

SN - 1521-6942

IS - 5

ER -